The contribution of inherited and acquired thrombophilic defects, alone or combined with antiphospholipid antibodies, to venous and arterial thromboembolism in patients with systemic lupus erythematosus

Blood

Volumn 104, Issue 1, 2004, Pages 143-148

  Brouwer, Jan Leendert P ^a   Bijl, Marc ^b   Veeger, Nic J G M ^b   Kluin Nelemans, Hanneke C ^b   Van Der Meer, Jan ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 5 LEIDEN; CARDIOLIPIN ANTIBODY; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; PROTEIN C; PROTEIN S; PROTHROMBIN;

ADULT; AGED; ANTITHROMBIN DEFICIENCY; ARTICLE; BLOOD CLOTTING FACTOR 5 DEFICIENCY; COHORT ANALYSIS; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; RISK ASSESSMENT; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOPHILIA; THROMBOSIS; VENOUS THROMBOEMBOLISM;

EID: 3042787713     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-11-4085     Document Type: Article

References (26)

1. Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 5-year period: a multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore). 1999;78:167-175.
2. Petri M, Rheinschmidt M, Whiting-O'Keefe Q, Hellman D, Corash L. The frequency of lupus anticoagulant in systemic lupus erythematosus: a study of sixty consecutive patients by activated partial thromboplastin time, Russell viper venom time, and anticardiolipin antibody level. Ann Intern Med. 1987;106:524-531.
3. Merkel PA, Chang Y, Pierangeli SS, Convery K, Harris EN, Polisson RP. The prevalence and clinical associations of anticardiolipin antibodies in a large inception cohort of patients with connective tissue diseases. Am J Med. 1996;101:576-583.
4. Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders: prevalence and clinical significance. Ann Intern Med. 1990;112:682-698.
5. Cervera R, Khamashta MA, Font J, et al. Systemic Lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore). 1993;72:113-124.
6. Rosendaal, FR. Venous thrombosis: a multicausal disease. Lancet. 1999;353:1167-1173.
7. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271-1277.
8. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI: a disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992;35:630-640.
9. Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996;39:363-369.
10. Exner T, Triplett DA, Taberner D, Machin SJ. Guidelines for testing and revised criteria for lupus anticoagulants. SSC Subcommittee for the Standardization of Lupus Anticoagulants. Thromb Haemost. 1991;65:320-322.
11. Bertina RM, Koeleman BPC, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64-67.
12. Danneberg J, Abbes AP, Bruggeman BJM, Engel H, Gerrits J, Martens A. Reliable genotyping of the G-20210-A mutation of coagulation factor II (prothrombin). Clin Chem. 1998;44:349-351.
13. Comp PC, Thurnau GR, Welsh J, Esmon CT. Functional and immunologic protein S levels are decreased during pregnancy. Blood. 1986;68:881-885.
14. Finazzi G, Brancaccio V, Moia M, et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am J Med. 1996;100:530-536.
15. Out HJ, van Vliet M, de Groot PG, Derksen RH. Prospective study of fluctuations of lupus anticoagulant activity and anticardiolipin antibody titre in patients with systemic lupus erythematosus. Ann Rheum Dis. 1992;51:353-357.
16. Rosenberg RD, Aird WC. Vascular-bed-specific hemostasis and hypercoagulable states. N Engl J Med. 1999;340:1555-1564.
17. Fijnheer R, Horbach DA, Donders RC, et al. Factor V Leiden, antiphospholipid antibodies and thrombosis in systemic lupus erythematosus. Thromb Haemost. 1996;76:514-517.
18. Regeczy N, Lakos G, Balogh I, Ajzner E, Kiss E, Szegedi G. The Leiden mutation of coagulation factor V in Hungarian SLE patients. Clin Appl Thromb Hemost. 2000;6:41-45.
19. Topaloglu R, Akierli C, Bakkaloglu A, et al. Survey of factor V Leiden and prothrombin gene mutations in systemic lupus erythematosus. Clin Rheumatol. 2001;20:259-261.
20. Nordstrom M, Lindblad B, Bergqvist D, Kjellstrom T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med. 1992;232:155-160.
21. Anderson FA, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med. 1991;151:933-938.
22. Dahlback B, Stenflo J. High molecular weight complex in human plasma between vitamin K-dependent protein S and complement component C4b-binding protein. Proc Natl Acad Sci U S A. 1981;78:2512-2516.
23. Muñoz-Rodríguez FJ, Reverter JC, Font J, et al. Clinical significance of acquired activated protein C resistance in patients with systemic lupus erythematosus. Lupus. 2002;11:730-735.
24. Male C, Mitchell L, Julian J, et al. Acquired activated protein C resistance is associated with lupus anticoagulants and thrombotic events in pedriatric patients with systemic lupus erythematosus. Blood. 2001;897:844-849.
25. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med. 1998;105:91-99.
26. Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISOCAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet. 1996;17:423-428.